Form 4: Baker Bros. Advisors LP Acquires Immunocore Holdings Options for Director Ranjeev Krishana

Baker Bros. Advisors LP reports the acquisition of non-qualified share options for Immunocore Holdings director Ranjeev Krishana, exercisable into ordinary shares, as part of the company's 2021 Equity Incentive Plan.

Summary

• Baker Bros. Advisors LP filed a Form 4 detailing the acquisition of non-qualified share options for Immunocore Holdings plc director Ranjeev Krishana.
• The options, totaling 26,198, are exercisable into ordinary shares of Immunocore Holdings.
• These options were granted on May 15, 2025, as part of Immunocore's 2021 Equity Incentive Plan.
• The strike price for the options is $29.06 per share.
• The options vest on the earlier of the first anniversary of the grant date or the day before the next annual shareholder meeting, contingent on Ranjeev Krishana's continued service on the board.
• The options expire on May 14, 2035.
• Ranjeev Krishana serves on the board as a representative of 667, L.P. and Baker Brothers Life Sciences, L.P.
• Baker Bros. Advisors LP has complete discretion over the investment and voting power of these securities.
• Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in these options due to their ownership interest in the general partners of the Funds.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding stock options. It doesn't contain overtly positive or negative information, hence a neutral sentiment score.

Positives

• The grant of share options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.
• The acquisition of options by Baker Bros. Advisors LP indicates their continued involvement and investment in Immunocore Holdings.

Future Outlook

The document does not contain specific forward-looking statements regarding Immunocore Holdings' future performance.

Industry Context

This filing is typical for companies with equity-based compensation plans for directors and key employees. It reflects the ongoing use of stock options as a tool to incentivize and retain talent within the biotechnology industry.

Comparison to Industry Standards

• Equity compensation is a common practice in the biotech industry, often used to attract and retain talent, especially in companies with high growth potential.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and restricted stock units as part of their compensation packages for directors and executives.
• The vesting schedules and strike prices are generally aligned with industry norms, aiming to incentivize long-term value creation.

Stakeholder Impact

• Shareholders may view the grant of stock options as a positive sign, aligning the director's interests with the company's long-term success.
• Employees may see this as a standard practice for incentivizing key personnel.
• The impact on customers, suppliers, and creditors is likely minimal.

Key Dates

Keywords

Immunocore Holdings, Baker Bros. Advisors LP, Share Options, Director Compensation, Equity Incentive Plan, Beneficial Ownership, Form 4